Reference is made to the stock exchange announcement made by Circio Holding
ASA (the "Company") on 15 September 2026, regarding key information relating
to a potential subsequent offering of up to 16,865,000 new shares in the
Company (the "Subsequent Offering").
The shares in Company will be traded exclusive of the right to participate in
the Subsequent Offering from and including today, 15 September 2026.
Ex. date: 15 September 2026
* * *
This information is published in accordance with the requirements of the
Continuing Obligations in Euronext Rule Book II.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: lubor.gaal@circio.com
About Circio
Building circular RNA expression systems for enhanced gene and cell therapies
Circio Holding ASA is a biotechnology company developing novel circular RNA
expression technology for gene and cell therapy.
Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic construct designed
for efficient biogenesis of multifunctional circRNA inside target cells. The
circVec platform has applications in multiple therapeutic settings, including
genetic medicine, cell therapy and chronic disease. It has demonstrated
75-fold increased RNA half-life and up to 60-fold enhanced protein expression
vs. conventional mRNA-based viral and non-viral vector systems, with the
potential to become a new gold-standard gene expression technology. The
circVec R&D activities are being conducted by the wholly owned subsidiary
Circio AB in Stockholm, Sweden.
ly owned subsidiary\
Circio AB in Stockholm\, Sweden.\